Previous 10 | Next 10 |
home / stock / mrvi / mrvi articles
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fi...
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to...
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and...
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services ...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.2% on Friday. The Dow traded up 0.23% to 39,158.52 w...
Thursday, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) reported fourth-quarter 2023 revenue of $74.1 million, beating the consens...
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The Dow traded up 0.36% t...
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Carvana Co. (NYSE: CVNA) rose sharply d...
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...
2024-05-29 15:15:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MRVI on May 29, 2024 01:35PM ET. The previous analyst recommendation was Outperform. MRVI was trading at $8.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...